Details for Patent: 9,006,387

Which drugs does patent 9,006,387 protect, and when does it expire?

Patent 9,006,387 protects VIEKIRA XR, TECHNIVIE, and VIEKIRA PAK (COPACKAGED), and is included in three NDAs.

This patent has two hundred and seventy-two patent family members in forty-five countries.

Summary for Patent: 9,006,387

Title:	Anti-viral compounds
Abstract:	Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
Inventor(s):	Wagner; Rolf (Antioch, IL), Pratt; John K. (Kenosha, IL), Liu; Dachun (Waukegan, IL), Tufano; Michael D. (Chicago, IL), DeGoey; David A. (Salem, WI), Kati; Warren M. (Gumee, IL), Hutchins; Charles W. (Green Oaks, IL), Donner; Pamela L. (Mundelein, IL), Randolph; John T. (Libertyville, IL), Motter; Christopher E. (Oak Creek, IL), Nelson; Lissa T. (Highland Park, IL), Patel; Sachin V. (Round Lake, IL), Matulenko; Mark A. (Libertyville, IL), Keddy; Ryan G. (Beach Park, IL), Jinkerson; Tammie K. (Pleasant Prairie, WI), Rockway; Todd W. (Grayslake, IL), Maring; Clarence J. (Palatine, IL), Hutchinson; Douglas K. (Antioch, IL), Flentge; Charles A. (Salem, WI), Betebenner; David A. (Libertyville, IL), Sarris; Kathy (Mundelein, IL), Woller; Kevin R. (Antioch, IL), Wagaw; Seble H. (Evanston, IL), Califano; Jean C. (Whitefish Bay, WI), Li; Wenke (Gumee, IL), Caspi; Daniel D. (Evanston, IL), Bellizzi; Mary E. (North Chicago, IL), Gao; Yi (Vernon Hills, IL), Krueger; Allan C. (Gumee, IL)
Assignee:	AbbVie Inc. (North Chicago, IL)
Application Number:	14/180,886
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,006,387
Patent Claim Types: see list of patent claims	Use;

Understanding the Scope and Claims of United States Patent 9,006,387

Introduction

United States Patent 9,006,387, titled "Anti-viral compounds," is a significant patent in the field of pharmaceuticals, particularly in the development of treatments for Hepatitis C virus (HCV). This article provides a detailed analysis of the scope and claims of this patent, as well as an overview of the patent landscape in this area.

Background

The patent, granted on April 14, 2015, describes compounds effective in inhibiting the replication of HCV, along with processes for making these compounds. Here, we will delve into the key aspects of the patent, including its claims, the chemical compounds involved, and the broader patent landscape.

Patent Claims

Overview of Claims

The patent includes multiple claims that define the scope of the invention. These claims are categorized into different types, including independent claims and dependent claims.

Independent Claims

Independent claims stand alone and define the invention without reference to other claims. For example, Claim 1 of the patent describes a compound of a specific chemical structure, which is effective in inhibiting HCV replication. This claim sets the foundation for the invention by specifying the core chemical composition of the anti-viral compounds[4].

Dependent Claims

Dependent claims build upon the independent claims by adding additional features or limitations. These claims further narrow down the scope of the invention. For instance, dependent claims might specify particular substituents or functional groups that can be added to the core chemical structure, enhancing the anti-viral efficacy or stability of the compounds[4].

Chemical Compounds

Chemical Structure

The patent details various chemical compounds that are effective against HCV. These compounds include a range of heterocyclic groups, halogens, and other functional groups such as cyano, nitro, and oxo groups. The specific chemical structures are crucial as they determine the efficacy and specificity of the compounds in inhibiting HCV replication[4].

Examples of Chemical Groups

• Heterocyclic Groups: These are ring structures that contain at least one heteroatom (an atom other than carbon or hydrogen). The patent specifies various heterocyclic groups that are part of the anti-viral compounds[4].
• Halogens: Halogen atoms such as fluorine, chlorine, and bromine are mentioned as part of the chemical structure. These halogens can be attached to the core structure in various positions[4].
• Cyano, Nitro, and Oxo Groups: These functional groups are also integral to the chemical structure of the compounds. They contribute to the overall pharmacological properties of the anti-viral agents[4].

Processes for Making the Compounds

The patent also describes the methods for synthesizing these anti-viral compounds. These processes involve various chemical reactions and steps to produce the desired compounds with high purity and efficacy. Understanding these processes is essential for reproducing the invention and for potential improvements or modifications[4].

Patent Landscape

Related Patents

The patent landscape in the area of anti-viral compounds, particularly for HCV, is highly competitive. There are numerous patents filed by various pharmaceutical companies and research institutions. These patents often overlap in terms of chemical structures and mechanisms of action, but each may have unique features or improvements.

Recent Developments

Recent years have seen significant advancements in the treatment of HCV, with several new drugs and therapies being developed. Patents like US 9,006,387 contribute to this landscape by providing new chemical entities and synthesis methods that can be used to combat the virus more effectively.

Legal and Regulatory Aspects

Patents in the pharmaceutical sector are subject to stringent legal and regulatory requirements. The USPTO's guidance on patent subject matter eligibility, such as the 2024 update focusing on AI and software-related technologies, also has implications for pharmaceutical patents, although these are more related to the method of invention development rather than the chemical compounds themselves[1].

Practical Applications

Clinical Use

The compounds described in the patent are designed for clinical use in treating HCV. The practical application involves administering these compounds to patients to inhibit the replication of the virus, thereby reducing the viral load and alleviating symptoms.

Real-World Benefits

The real-world benefits of these compounds include improved treatment outcomes for HCV patients. By providing effective anti-viral agents, these compounds can help in reducing the morbidity and mortality associated with HCV infections.

Key Takeaways

• Specific Chemical Structures: The patent specifies detailed chemical structures of anti-viral compounds effective against HCV.
• Synthesis Methods: The patent includes methods for synthesizing these compounds, which is crucial for their production.
• Patent Claims: The claims define the scope of the invention, including independent and dependent claims.
• Patent Landscape: The patent is part of a broader landscape of anti-viral compounds, with ongoing research and development in this area.
• Clinical Use: The compounds are designed for clinical use in treating HCV, offering improved treatment outcomes.

FAQs

What is the main focus of United States Patent 9,006,387?

The main focus of this patent is on anti-viral compounds effective in inhibiting the replication of Hepatitis C virus (HCV), along with processes for making these compounds.

What types of chemical groups are mentioned in the patent?

The patent mentions various chemical groups including heterocyclic groups, halogens, cyano, nitro, and oxo groups.

How do the claims in the patent define the scope of the invention?

The claims in the patent define the scope by specifying the core chemical composition and additional features or limitations through independent and dependent claims.

What is the significance of the synthesis methods described in the patent?

The synthesis methods are crucial for producing the anti-viral compounds with high purity and efficacy, allowing for their practical application in treating HCV.

How does this patent fit into the broader patent landscape for anti-viral compounds?

This patent is part of a highly competitive landscape of anti-viral compounds for HCV, contributing new chemical entities and synthesis methods to the existing body of knowledge.

Sources

1. Understanding the 2024 USPTO Guidance Update on AI Patent: Mintz, July 25, 2024.
2. Charles W. Hutchins Inventions, Patents and Patent Applications: Justia Patents.
3. Patent Claims Research Dataset: USPTO, August 28, 2017.
4. US9006387B2 - Anti-viral compounds: Google Patents.

Drugs Protected by US Patent 9,006,387

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016		DISCN	Yes	No	9,006,387					TREATMENT OF HCV INFECTION USING OMBITASVIR
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No	9,006,387					TREATMENT OF HCV INFECTION USING OMBITASVIR
Abbvie	VIEKIRA PAK (COPACKAGED)	dasabuvir sodium; ombitasvir, paritaprevir, ritonavir	TABLET;ORAL	206619-001	Dec 19, 2014		DISCN	Yes	No	9,006,387					TREATMENT OF HCV INFECTION USING OMBITASVIR

International Family Members for US Patent 9,006,387

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2368890		PA2015012	Lithuania
European Patent Office	2368890		CA 2015 00015	Denmark
European Patent Office	2368890		C02368890/01	Switzerland
European Patent Office	2368890		15C0016	France